Kimberly Haire
Family · Mesquite, TXNPI 1619348216
Payments from drug & device makers
Across 472 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$931
- Amgen$819
- Novo Nordisk$779
- Boehringer Ingelheim$617
- AstraZeneca$441
- AbbVie$411
- plus $4K from 43 others
What the payments were for
- Food & beverage$8,331100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$121
How this compares
$8,331 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 177 | $264,206 |
| OzempicSemaglutide | 151 | $248,159 |
| TrulicityDulaglutide | 69 | $105,639 |
| JardianceEmpagliflozin | 60 | $78,651 |
| Tresiba Flextouch U-100Insulin Degludec | 74 | $63,042 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $34,048 |
| FarxigaDapagliflozin Propanediol | 29 | $25,482 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $25,144 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $19,844 |
| RybelsusSemaglutide | 16 | $19,826 |
| Humalog Kwikpen U-100Insulin Lispro | 49 | $18,948 |
| JanuviaSitagliptin Phosphate | 18 | $16,342 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $16,305 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 43 | $15,865 |
| Gvoke Hypopen 1-PackGlucagon | 11 | $13,940 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $931 | $373,818259 claims |
| Novo NordiskOzempic, Rybelsus | $779 | $267,985167 claims |
| Boehringer IngelheimJardiance | $617 | $78,65160 claims |
| AstraZenecaFarxiga | $441 | $25,48229 claims |
| MerckJanuvia | $127 | $16,34218 claims |
| AbbVieSynthroid | $411 | $78711 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $211 | $34339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Mesquite
- Corina SturgeonMesquite$38K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.